Medical Research
Bank of The West Cuts Stock Position in Amgen Inc. (NASDAQ:AMGN) | 11/12/2020
… reduced its position in Amgen Inc. (NASDAQ:AMGN) by 11.6% in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 3,008 shares of the medical research company‚Äôs stock after selling 394 shares during the quarter. Bank of The West‚Äôs holdings in Amgen were worth $765,000 at the end of the most recent quarter. Several other hedge funds and …
Signet Financial Management LLC Has $1.50 Million Holdings in Amgen Inc. (NASDAQ:AMGN) | 11/12/2020
Signet Financial Management LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,496 shares of the medical research company‚Äôs stock after selling 1,377 shares during the quarter. Signet Financial Management LLC‚Äôs holdings in Amgen were worth $1,496,000 as of its most recent SEC filing …
Sentry Investment Management LLC Acquires 3,518 Shares of Amgen Inc. (NASDAQ:AMGN) | 11/12/2020
Sentry Investment Management LLC lifted its holdings in Amgen Inc. (NASDAQ:AMGN) by 10.3% in the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 37,830 shares of the medical research company‚Äôs stock after acquiring an additional 3,518 shares during the period. Sentry Investment Management LLC‚Äôs holdings in Amgen were worth $9,615,000 at the end of the most …
Amgen Inc. (NASDAQ:AMGN) Shares Sold by CIBC Asset Management Inc | 11/12/2020
CIBC Asset Management Inc reduced its stake in shares of Amgen Inc. (NASDAQ:AMGN) by 14.8% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 106,692 shares of the medical research company‚Äôs stock after selling 18,563 shares during the quarter. CIBC Asset Management Inc‚Äôs holdings in Amgen were worth $27,117,000 as of its most recent filing …
Signet Financial Management LLC Has $1.50 Million Holdings in Amgen Inc. (NASDAQ:AMGN) | 11/12/2020
Signet Financial Management LLC trimmed its position in shares of Amgen Inc. (NASDAQ:AMGN) by 17.5% during the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 6,496 shares of the medical research company‚Äôs stock after selling 1,377 shares during the quarter. Signet Financial Management LLC‚Äôs holdings in Amgen were worth $1,496,000 as of its most recent SEC filing …
… to suppress transmission of COVID-19 among young adults , whether in military training , schools, or other aspects of the pandemic. The researchers from the Icahn School of Medicine at Mount Sinai and the Naval Medical Research Center studied new Marine recruits while they were in a two-week supervised quarantine. The study results, publishing November 11 in The New England Journal of Medicine , showed that few infected recruits had symptoms …
Many military Covid-19 cases are asymptomatic, studies show | MSN | 11/12/2020
… likely played a big role in outbreaks. Marine recruits in quarantine get sick Packed living conditions likely aided the rapid spread of the virus, the researchers said. One study – by researchers at the Naval Medical Research Center, Icahn School of Medicine at Mount Sinai and other institutions – included data on 1,848 recruits who were tested for Covid-19 after completing a two-week quarantine at home and then throughout a …
… will be available by the third week of November. Coronavirus Covid 19 vaccine update India Covaxin In India, our indigenous Coronavirus vaccine candidate Covaxin, jointly developed by Bharat Biotech and the Indian Council of Medical Research (ICMR), has entered the third phase of the Human trial. The trial is set to begin at Aligarh Muslim University‚Äôs (AMU) JN Medical College and Hospital (JNMCH). It has been learned that Vice …
VA Joins Pentagon in Recruiting Volunteers for COVID Vaccine Trials | Physicians Weekly | 11/11/2020
… facilities, which are separate from the VA system. DOD is also is in talks with developers of other vaccine candidates, although officials won‚Äôt say which ones. Both federal departments have long experience in medical research and diverse populations ‚Äî a crucial component of effective clinical trials, said J. Stephen Morrison, senior vice president and director of global health policy at the Center for Strategic and International Studies, a bipartisan …
… of 0.92. Edwards Lifesciences Co. has a 1 year low of $51.51 and a 1 year high of $87.79. Edwards Lifesciences (NYSE:EW) last posted its quarterly earnings data on Wednesday, October 21st. The medical research company reported $0.51 earnings per share (EPS) for the quarter, topping the Thomson Reuters‚Äô consensus estimate of $0.45 by $0.06. Edwards Lifesciences had a return on equity of 29.00% and a net margin …
Tissue Banking Market explored in the latest research by key player BioCision, EPL Archives., Brooks Automation, Bluechiip Limited, BioKryo iCrowdNewswire Nov 11, 202012:00 AM ET A tissue bank is an establishment that collects and recovers human cadaver tissue for the purposes of medical research , education, and allograft transplantation. A tissue bank may also refer to a location where biomedical tissue is stored under cryogenic conditions, and is generally used in …
Seelaus Asset Management LLC trimmed its position in Thermo Fisher Scientific Inc. (NYSE:TMO) by 5.7% during the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 5,002 shares of the medical research company‚Äôs stock after selling 300 shares during the quarter. Thermo Fisher Scientific accounts for approximately 1.8% of Seelaus Asset Management LLC‚Äôs portfolio …
Dakota Wealth Management Reduces Stock Holdings in Amgen Inc. (NASDAQ:AMGN) | 11/11/2020
… its position in Amgen Inc. (NASDAQ:AMGN) by 86.6% in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 911 shares of the medical research company‚Äôs stock after selling 5,907 shares during the quarter. Dakota Wealth Management‚Äôs holdings in Amgen were worth $232,000 at the end of the most recent reporting period. Several other institutional investors and …
Missouri S&T to host virtual ‘Future of Cancer Summit’ | 11/11/2020
… Nobel Prize in chemistry, and its future applications in cancer care. ‚ÄúThe Ozark Biomedical Initiative highlights the transformative work our own community is doing to innovate healthcare,‚Äù says Dr. Casey Burton, director of medical research at Phelps Health and adjunct assistant professor at Missouri S&T. ‚ÄúWe are excited to have partnered with Siteman Cancer Center on this year‚Äôs summit to build new collaborations and research opportunities for …
5 important questions about Pfizer’s COVID-19 vaccine | FiercePharma | 11/11/2020
… trials of its own mRNA vaccine against COVID-19. ‚ÄúWe now have a whole new class of vaccines in our hands.‚Äù But historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that have undergone extensive scrutiny about study design, results and assumptions, not through company press releases. So did Pfizer‚Äôs stock deserve its double-digit percentage bump? The answers to the following five …
Five reasons we must increase diversity in medical research | 11/11/2020
… to understand that research has existed since the advent of modern-day medicine. It is through research that we learn if a treatment is safe and works as it is supposed to. Participation in medical research is particularly important if you are from a racially and/or ethnically diverse background because these groups have been historically underrepresented. Here are five reasons why this matters and what you can do for …
RadNet, Inc. (NASDAQ:RDNT) ‚Äì Stock analysts at Jefferies Financial Group cut their FY2021 EPS estimates for shares of RadNet in a research note issued to investors on Monday, November 9th. Jefferies Financial Group analyst B. Tanquilut now anticipates that the medical research company will earn $0.41 per share for the year, down from their prior estimate of $0.45. Get RadNet alerts: Several other equities research analysts have also recently …
… advanced trials of its own mRNA vaccine against COVID-19. “We now have a whole new class of vaccines in our hands.” But historically, important scientific announcements about vaccines are made through peer-reviewed medical research papers that have undergone extensive scrutiny about study design, results and assumptions, not through company press releases. So did Pfizer’s stock deserve its double-digit percentage bump? The answers to the following five questions …
PerkinElmer (NYSE:PKI) Receives New Coverage from Analysts at KeyCorp | 11/10/2020
Investment analysts at KeyCorp began coverage on shares of PerkinElmer (NYSE:PKI) in a report released on Monday, The Fly reports. The brokerage set a ‚Äúsector weight‚Äù rating on the medical research company‚Äôs stock. PKI has been the topic of several other research reports. Smith Barney Citigroup upped their target price on shares of PerkinElmer from $120.00 to $140.00 in a research note on Thursday, October 29th. Cfra …
Slow Capital Inc. Boosts Stock Holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) | 11/10/2020
Tweet Slow Capital Inc. raised its holdings in Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.8% in the 3rd quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 6,965 shares of the medical research company‚Äôs stock after purchasing an additional 120 shares during the period. Slow Capital Inc.‚Äôs holdings in Thermo Fisher Scientific were worth $3,075,000 at the end …
Brazil’s health regulator said on Monday it had suspended clinical trials for China’s Sinovac coronavirus vaccine, due to a “severe adverse effect” that took place on Oct. 29 but did not immediately provide further details. Sao Paulo’s medical research institute Butantan, which is conducting the Sinovac trials in Brazil, said it “was surprised” by the decision and would hold a news conference on Tuesday at 11 a.m. local time (1400 …
KeyCorp Begins Coverage on Thermo Fisher Scientific (NYSE:TMO) - TheOlympiaReport | 11/10/2020
Investment analysts at KeyCorp started coverage on shares of Thermo Fisher Scientific (NYSE:TMO) in a report issued on Monday, The Fly reports. The brokerage set a ‚Äúsector weight‚Äù rating on the medical research company‚Äôs stock. Other equities analysts have also recently issued reports about the stock. Morgan Stanley lifted their price target on shares of Thermo Fisher Scientific from $485.00 to $535.00 and gave the stock an …
V.A. Recruits Volunteers for COVID Vaccine Trials | 11/10/2020
… facilities, which are separate from the VA system. DOD is also is in talks with developers of other vaccine candidates, although officials won‚Äôt say which ones. Both federal departments have long experience in medical research and diverse populations ‚Äî a crucial component of effective clinical trials, said J. Stephen Morrison, senior vice president and director of global health policy at the Center for Strategic and International Studies, a bipartisan …
Brazil paused its clinical trials of Sinovac’s coronavirus vaccine candidate on Monday, following a death. Brazil’s Butantan medical research institute has been working with the Chinese private biotech on clinical trials of its vaccine in S√£o Paolo since July. But Anvisa, Brazil’s health regulator, said on Monday that a “serious adverse event” occured on October 29 and that the trial was now suspended. Buntantan director Dimas Covas said a …
Advancing neuroscience at Mayo Clinic in Florida: Dr. Sandro Da Mesquita | 11/10/2020
… building and hopes team science leads to new approaches aimed at preventing neurodegeneration and cognitive decline in patients. His research focuses on neuroscience and neuroimmunology. Here he explains what guided him to pursue a medical research career. What is your background? I am a biochemist by training and performed all of my graduate studies in Portugal, at the School of Medicine of the University of Minho, located in a northern …
About:
Editor:
